ATE135743T1 - Monoklonale menschliche antikörper gegen hiv-i - Google Patents

Monoklonale menschliche antikörper gegen hiv-i

Info

Publication number
ATE135743T1
ATE135743T1 AT89900809T AT89900809T ATE135743T1 AT E135743 T1 ATE135743 T1 AT E135743T1 AT 89900809 T AT89900809 T AT 89900809T AT 89900809 T AT89900809 T AT 89900809T AT E135743 T1 ATE135743 T1 AT E135743T1
Authority
AT
Austria
Prior art keywords
human antibodies
antibodies against
against hiv
monoclonal human
ecacc accession
Prior art date
Application number
AT89900809T
Other languages
English (en)
Inventor
Hermann Katinger
Baehr Ruediger Von
Alois Jungbauer
Tomas Porstmann
Franz J Steindl
Roland Grunow
Andrea Buchacher
Original Assignee
Hermann Katinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hermann Katinger filed Critical Hermann Katinger
Application granted granted Critical
Publication of ATE135743T1 publication Critical patent/ATE135743T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89900809T 1987-11-13 1988-11-14 Monoklonale menschliche antikörper gegen hiv-i ATE135743T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12048987A 1987-11-13 1987-11-13

Publications (1)

Publication Number Publication Date
ATE135743T1 true ATE135743T1 (de) 1996-04-15

Family

ID=22390624

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89900809T ATE135743T1 (de) 1987-11-13 1988-11-14 Monoklonale menschliche antikörper gegen hiv-i

Country Status (6)

Country Link
US (1) US5753503A (de)
EP (1) EP0355140B1 (de)
JP (1) JPH02502251A (de)
AT (1) ATE135743T1 (de)
DE (1) DE3855134T2 (de)
WO (1) WO1989004370A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
AT396939B (de) * 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
AU641814B2 (en) * 1990-09-25 1993-09-30 Peptech (Uk) Limited Aids therapy and vaccine
GB9113475D0 (en) * 1991-06-21 1991-08-07 Hafslund Nycomed As Chemical compound
WO1994004574A1 (en) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
ATE219105T1 (de) * 1995-04-19 2002-06-15 Polymun Scient Immunbio Forsch Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
ATE516048T1 (de) 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
EP3996815A2 (de) 2019-07-15 2022-05-18 Lausanne University Hospital Hiv-bindemittel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087557A (en) * 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
DK169582B1 (da) * 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant

Also Published As

Publication number Publication date
EP0355140A1 (de) 1990-02-28
DE3855134T2 (de) 1996-10-02
JPH02502251A (ja) 1990-07-26
US5753503A (en) 1998-05-19
EP0355140B1 (de) 1996-03-20
WO1989004370A1 (en) 1989-05-18
DE3855134D1 (de) 1996-04-25

Similar Documents

Publication Publication Date Title
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
DE69334148D1 (de) HIV-Peptide
ATE380822T1 (de) Funf-helix protein
DE3853779D1 (de) Hiv-1 neutralisierende monoklonale antikörper.
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ES8705522A1 (es) Un procedimiento para la preparacion de derivados purificados de una glicoproteina.
ATE183515T1 (de) Zusammensetzungen die die hiv replikation inhibieren
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
WO1989006276A3 (en) Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
EP0345462A3 (de) Immuntest für HIV-1-Antigene unter Benutzung von F(AB')2-Fragmenten als Sonde
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
DE69332911D1 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
DK0541753T3 (da) Hidtil ukendt hybrid, opløselig og ikke-spaltelig gp160-variant
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
DK90090D0 (da) Fremgangsmaade til fremstilling af naturligt hiv gp160
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
ATE80553T1 (de) Behandlung von viraler infektion.
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee